Cargando…
Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, sugge...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404995/ https://www.ncbi.nlm.nih.gov/pubmed/34175955 http://dx.doi.org/10.1093/toxsci/kfab084 |
_version_ | 1783746246669762560 |
---|---|
author | Ogese, Monday O Lister, Adam Gardner, Joshua Meng, Xiaoli Alfirevic, Ana Pirmohamed, Munir Park, B Kevin Naisbitt, Dean J |
author_facet | Ogese, Monday O Lister, Adam Gardner, Joshua Meng, Xiaoli Alfirevic, Ana Pirmohamed, Munir Park, B Kevin Naisbitt, Dean J |
author_sort | Ogese, Monday O |
collection | PubMed |
description | Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T cells. The purpose of this study was to utilize peripheral blood mononuclear cell from healthy donors to: (1) investigate whether expression of HLA-A*32:01 is critical for the priming naïve of T cells with vancomycin and (2) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity. Dendritic cells were cultured with naïve T cells and vancomycin for 2 weeks. On day 14, cells were restimulated with vancomycin and T-cell proliferation was assessed by [(3)H]-thymidine incorporation. Vancomycin-specific TCC were generated by serial dilution and repetitive mitogen stimulation. Naïve T cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01. Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN‐γ, IL-13, and cytolytic molecules. Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing. Several TCC displayed cross-reactivity with teicoplanin and daptomycin. To conclude, this study provides evidence that vancomycin primes naïve T cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction. Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients. |
format | Online Article Text |
id | pubmed-8404995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84049952021-09-01 Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 Ogese, Monday O Lister, Adam Gardner, Joshua Meng, Xiaoli Alfirevic, Ana Pirmohamed, Munir Park, B Kevin Naisbitt, Dean J Toxicol Sci Immunotoxicology Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T cells. The purpose of this study was to utilize peripheral blood mononuclear cell from healthy donors to: (1) investigate whether expression of HLA-A*32:01 is critical for the priming naïve of T cells with vancomycin and (2) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity. Dendritic cells were cultured with naïve T cells and vancomycin for 2 weeks. On day 14, cells were restimulated with vancomycin and T-cell proliferation was assessed by [(3)H]-thymidine incorporation. Vancomycin-specific TCC were generated by serial dilution and repetitive mitogen stimulation. Naïve T cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01. Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN‐γ, IL-13, and cytolytic molecules. Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing. Several TCC displayed cross-reactivity with teicoplanin and daptomycin. To conclude, this study provides evidence that vancomycin primes naïve T cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction. Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients. Oxford University Press 2021-06-27 /pmc/articles/PMC8404995/ /pubmed/34175955 http://dx.doi.org/10.1093/toxsci/kfab084 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Immunotoxicology Ogese, Monday O Lister, Adam Gardner, Joshua Meng, Xiaoli Alfirevic, Ana Pirmohamed, Munir Park, B Kevin Naisbitt, Dean J Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title_full | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title_fullStr | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title_full_unstemmed | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title_short | Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 |
title_sort | deciphering adverse drug reactions: in vitro priming and characterization of vancomycin-specific t cells from healthy donors expressing hla-a*32:01 |
topic | Immunotoxicology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404995/ https://www.ncbi.nlm.nih.gov/pubmed/34175955 http://dx.doi.org/10.1093/toxsci/kfab084 |
work_keys_str_mv | AT ogesemondayo decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT listeradam decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT gardnerjoshua decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT mengxiaoli decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT alfirevicana decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT pirmohamedmunir decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT parkbkevin decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 AT naisbittdeanj decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201 |